Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857549 | 0.90 | TRPV1 (0.41) | TRPV1MAOAKCNH2GAAPOLB | |
| SCHEMBL1869242 | 0.89 | TRPV1 (0.53) | TRPV1MAOAKCNH2MAP3K12MAPK3 | |
| SCHEMBL1858388 | 0.87 | TRPV1 (0.49) | TRPV1MAOAKCNH2MAPK3RPS6KA3 | |
| SCHEMBL3956119 | 0.86 | TRPV1 (0.64) | TRPV1MAOAKCNH2MAP3K12MAPK3 | |
| SCHEMBL1862250 | 0.80 | TRPV1 (0.46) | TRPV1MAOAKCNH2MAPK3RPS6KA3 | |
| SCHEMBL1862905 | 0.80 | TRPV1 (0.45) | TRPV1MAOAKCNH2 | |
| SCHEMBL1856617 | 0.78 | TRPV1 (0.66) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL1860183 | 0.78 | TRPV1 (0.44) | TRPV1MAPK3MEN1KMT2A | |
| SCHEMBL12666713 | 0.78 | TRPV1 (0.40) | TRPV1MAOAKCNH2 | |
| SCHEMBL1868084 | 0.77 | TRPV1 (0.73) | TRPV1MAOAKCNH2MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | TRPV1 549/4885MAOA 582/4885KCNH2 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.